1. Hilts, P. J. (2003). Protecting America’s health: The FDA, business, and one hundred years of regulation. Knopf.
2. US Food and Drug Administration. (2019). FDA history: Part I: The 1906 food and drugs act and its enforcement. https://www.fda.gov/about-fda/fdas-evolving-regulatory-powers/part-i-1906-food-and-drugs-act-and-its-enforcement. (Last updated 24 April 2019) Last accessed 6 Mar 2021.
3. US Food and Drug Administration. (2020, July). Regulatory considerations for human cell, tissues, and cellular and tissue-based products: Minimal manipulation and homologous use, guidance for industry and FDA staff. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/regulatory-considerations-human-cells-tissues-and-cellular-and-tissue-based-products-minimal. (Last updated 21 July 2020) Last accessed 6 Mar 2021.
4. Turner, L. (2017). ClinicalTrials.gov, stem cells and ‘pay-to participate’ clinical studies. Regenerative Medicine, 12(6), 705–719.
5. Knoepfler, P. (2021, February 28). Regenerative reads: Brain organoids, Clinicaltrials.gov change. The Niche: Knoepfler Lab Stem Cell Blog. https://ipscell.com/2021/02/regenerative-reads-brain-organoids-clinicaltrials-gov-change/. Last accessed 6 Mar 2021.